西妥昔單抗 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "西妥昔單抗" in Chinese language version.

refsWebsite

Global rank Chinese rank

6web.archive.org

1^st place

1^st place

2merckserono.com.tw

low place

low place

2^nd place

23^rd place

447^th place

581^st place

1biomedcentral.com

2,747^th place

1,988^th place

2,374^th place

1,457^th place

4^th place

5^th place

low place

low place

low place

low place

low place

low place

biomedcentral.com

Gonçalves, A. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.. BMC Cancer. 2008, 8: 169–179 [2011-12-13]. doi:10.1186/1471-2407-8-169. （原始内容存档于2015-08-18）.

dako.com

EGFR pharmDx™ Interpretation Manual (PDF). Dako. [2012-08-24]. （原始内容存档 (PDF)于2016-03-04）（英语）.

doi.org

dx.doi.org

Gonçalves, A. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.. BMC Cancer. 2008, 8: 169–179 [2011-12-13]. doi:10.1186/1471-2407-8-169. （原始内容存档于2015-08-18）.
Schrag, D. The price tag on progress – chemotherapy for colorectal cancer. New England Journal of Medicine. July 2004, 351 (4): 317–319. PMID 15269308. doi:10.1056/NEJMp048143. （原始内容存档于2010-04-27）.

fda.gov

accessdata.fda.gov

Label for Erbitux. (PDF). U.S FDA: 2. 2009年7月 [2011-12-13]. （原始内容存档 (PDF)于2021-03-31）（英语）.

merckserono.com.tw

nejm.org

content.nejm.org

Schrag, D. The price tag on progress – chemotherapy for colorectal cancer. New England Journal of Medicine. July 2004, 351 (4): 317–319. PMID 15269308. doi:10.1056/NEJMp048143. （原始内容存档于2010-04-27）.

nih.gov

ncbi.nlm.nih.gov

Schrag, D. The price tag on progress – chemotherapy for colorectal cancer. New England Journal of Medicine. July 2004, 351 (4): 317–319. PMID 15269308. doi:10.1056/NEJMp048143. （原始内容存档于2010-04-27）.

stpi.org.tw

cdnet.stpi.org.tw

標靶藥物大躍進. [2011-12-13]. （原始内容存档于2012-01-26）.

tccf.org.tw

王緯書. 轉移性大腸直腸癌治療的新希望－標靶治療藥物「爾必得舒」（Erbitux）. 台北榮民總醫院內科部血液腫瘤科. [2011-12-15]. （原始内容存档于2016-03-04）.

web.archive.org

Label for Erbitux. (PDF). U.S FDA: 2. 2009年7月 [2011-12-13]. （原始内容存档 (PDF)于2021-03-31）（英语）.
Gonçalves, A. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.. BMC Cancer. 2008, 8: 169–179 [2011-12-13]. doi:10.1186/1471-2407-8-169. （原始内容存档于2015-08-18）.
Schrag, D. The price tag on progress – chemotherapy for colorectal cancer. New England Journal of Medicine. July 2004, 351 (4): 317–319. PMID 15269308. doi:10.1056/NEJMp048143. （原始内容存档于2010-04-27）.
標靶藥物大躍進. [2011-12-13]. （原始内容存档于2012-01-26）.
王緯書. 轉移性大腸直腸癌治療的新希望－標靶治療藥物「爾必得舒」（Erbitux）. 台北榮民總醫院內科部血液腫瘤科. [2011-12-15]. （原始内容存档于2016-03-04）.
EGFR pharmDx™ Interpretation Manual (PDF). Dako. [2012-08-24]. （原始内容存档 (PDF)于2016-03-04）（英语）.